CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker

被引:105
作者
Landras, Alexandra [1 ]
de Moura, Coralie Reger [1 ,2 ]
Jouenne, Fanelie [1 ,2 ]
Lebbe, Celeste [1 ,3 ,4 ]
Menashi, Suzanne [1 ,2 ]
Mourah, Samia [1 ,2 ]
机构
[1] Univ Paris, INSERM UMRS 976, Team 1, HIPI, F-75010 Paris, France
[2] St Louis Hosp, AP HP, Pharmacogen Dept, F-75010 Paris, France
[3] St Louis Hosp, AP HP, Dermatol Dept, F-75010 Paris, France
[4] St Louis Hosp, AP HP, CIC, F-75010 Paris, France
关键词
CD147; biomarker; tumor microenvironment; prognosis; targeted therapy; MATRIX METALLOPROTEINASE INDUCER; CISPLATIN-CONTAINING CHEMOTHERAPY; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODIES; BASIGIN CD147; LUNG-CANCER;
D O I
10.3390/cancers11111803
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Microenvironment plays a crucial role in tumor development and progression. Cancer cells modulate the tumor microenvironment, which also contribute to resistance to therapy. Identifying biomarkers involved in tumorigenesis and cancer progression represents a great challenge for cancer diagnosis and therapeutic strategy development. CD147 is a glycoprotein involved in the regulation of the tumor microenvironment and cancer progression by several mechanisms-in particular, by the control of glycolysis and also by its well-known ability to induce proteinases leading to matrix degradation, tumor cell invasion, metastasis and angiogenesis. Accumulating evidence has demonstrated the role of CD147 expression in tumor progression and prognosis, suggesting it as a relevant tumor biomarker for cancer diagnosis and prognosis, as well as validating its potential as a promising therapeutic target in cancers.
引用
收藏
页数:17
相关论文
共 132 条
[1]   Identification of ADAM12 as a Novel Basigin Sheddase [J].
Albrechtsen, Reidar ;
Albrechtsen, Nicolai J. Wewer ;
Gnosa, Sebastian ;
Schwarz, Jeanette ;
Dyrskjot, Lars ;
Kveiborg, Marie .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (08)
[2]  
Allikmets R, 1998, CANCER RES, V58, P5337
[3]   Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer [J].
Als, Anne B. ;
Dyrskjot, Lars ;
von der Maase, Hans ;
Koed, Karen ;
Mansilla, Francisco ;
Toldbod, Helle E. ;
Jensen, Jens L. ;
Ulhoi, Benedicte P. ;
Sengelov, Lisa ;
Jensen, Klaus M. E. ;
Orntoft, Torben F. .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4407-4414
[4]   CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts [J].
Aoki, M. ;
Koga, K. ;
Miyazaki, M. ;
Hamasaki, M. ;
Koshikawa, N. ;
Oyama, M. ;
Kozuka-Hata, H. ;
Seiki, M. ;
Toole, B. P. ;
Nabeshima, K. .
BMC CANCER, 2019, 19 (01)
[5]  
Arora Manika, 2018, J Oral Maxillofac Pathol, V22, P279, DOI 10.4103/jomfp.JOMFP_129_17
[6]   Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism [J].
Baba, Miyako ;
Inoue, Masahiro ;
Itoh, Kazuyuki ;
Nishizawa, Yasuko .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 374 (01) :111-116
[7]   Common cancer biomarkers [J].
Basil, CF ;
Zhao, YD ;
Zavaglia, K ;
Jin, P ;
Panelli, MC ;
Voiculescu, S ;
Mandruzzato, S ;
Lee, HM ;
Seliger, B ;
Freedman, RS ;
Taylor, PR ;
Hu, N ;
Zanovello, P ;
Marincola, FM ;
Wang, E .
CANCER RESEARCH, 2006, 66 (06) :2953-2961
[8]   Basigin-2 is a cell surface receptor for soluble basigin ligand [J].
Belton, Robert J., Jr. ;
Chen, Li ;
Mesquita, Fernando S. ;
Nowak, Romana A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (26) :17805-17814
[9]   Generation of monoclonal antibodies to integrin-associated proteins - Evidence that alpha(3)beta(1) complexes with EMMPRIN/basigin/OX47/M6 [J].
Berditchevski, F ;
Chang, S ;
Bodorova, J ;
Hemler, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (46) :29174-29180
[10]  
BISWAS C, 1995, CANCER RES, V55, P434